Weight loss and the benefits Nutritional, Metabolic, Endocrine
Conditions
Interventions
This internal, prospective, non-randomized, non-blinded, dynamic, cohort observational study was conducted at Dr Sharon Giese’s aesthetic medicine practice located in New York City, from May 2022 unti
Sponsors
Sharon Giese, MD
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who were unable to attain their desired weight loss by any other means 2. 21 years old and over 3. Participants must agree to follow the prescribed treatment protocol, including weekly communication with a nutritional coach, weighing themselves, and adherence to medication dosage guidelines. 4. Participants who are taking semaglutide off-label must have consented and acknowledged the potential risks and outcomes.
Exclusion criteria
Exclusion criteria: 1. Pregnancy or breastfeeding 2. Taking medications such as metformin 3. Type 1 or type 2 diabetes or any other single co-morbidity 4. Individuals with BMI 40 5. A history of eating disorders 6. Severe gastrointestinal disorders 7. Severe adverse reactions to GLP-1 agonists, or other medical conditions that would pose a risk in a weight loss program 8. Unable to comply with follow-up procedures
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weight loss is measured by the participant taking their weight using a digital scale each morning. Patients have a recording sheet to record their weekly weight and medication dose. A photo is taken of the digital scale weight at days 0, 45, 180, and one and 2 years. | — |
Secondary
| Measure | Time frame |
|---|---|
| Defining the success of the weight loss program: Weight maintenance within the success zone will be assessed using regular weight measurements at baseline, 6 months, 1 year, and 2 years | — |
Countries
United States of America
Contacts
Public ContactSharon Giese
Outcome results
None listed